Press Release / February 10th, 2023 Vancouver, BC – Cube Psytech Holdings Inc. (the “Company” or “CUBE”), a biopharmaceutical and biotechnology company focused on the research and development of functional and psychedelic mushroom technologies for use in natural healthcare products, is pleased to announce that it has entered into a letter of intent (“LOI”) to acquire Translational Life Sciences (“TLS”). TLS will join Cube Psytech Corp. and Cube Wellness Products Inc. under the umbrella of the Cube group of companies. Under the LOI, CUBE will issue approximately 50% of its outstanding shares, warrants and options to shareholders, directors and employees of TLS in exchange for 100% of the outstanding share capital of TLS resulting in TLS acquiring one third of the share capital in CUBE. The acquisition is conditional on CUBE completing a private placement or other financing of a minimum of $2 million. CUBE believes that the acquisition of TLS will greatly strengthen CUBE’s position in the areas of psychedelic research and development. TLS is a science first company comprised of a top-notch team of scientists and technologists with R&D labs at the University of British Columbia. Highlights of TLS work in their whole drug discovery pipeline include: Successful profiling of over 1,000 extracted botanical compounds 2.5 years of brain receptor profiling data on over 200 species of mushrooms in cell culture and animals. Health Canada approved Dealer License that allows commercial scalability of production and product development in various psilocybin-based drugs. Proprietary efficacy and consistency testing protocols that insure natural functional and psychedelic products result in clinical grade standards suitable for global market. TLS’ primary focus has been, and will continue to be, the creation of intellectual property and patented psychedelic drug therapies used to help patients manage a variety of mental health issues in addition to concussions, eating disorders, obesity, and diabetes. “As a company our mission is to create products that help people and in TLS we have found a great partner in this mission. TLS is developing technologies that will help us create and bring to market important products that truly make a difference. With this strengthened combined team we will continue to lead the field in terms of science and business development and take a huge step forward as a company” states CUBE Co-Founder and CEO, Erick Factor “TLS is excited to be joining forces with Cube Psytech. Our common mission is to translate psychedelic science from the bench to the bedside. We look forward to joining their talented team to bring best-in-class naturally derived therapeutics to market” states TLS President and Founder, Dr. William Panenka, The Company also announces that is has initiated a private placement to issue up to 16,000,000 unit for gross proceeds of $4,000,000 at a price of $0.25 per unit. Each unit is comprised of one common share of the Company and one-half warrant. Each full warrant will have an exercise price of $0.40 per share and will expire three years after issue date. Proceeds from the private placement will be used for working capital purposes to fund operations, continue development on its property in Ontario, and to pursue a listing on a public exchange. On Behalf of The Board of Directors Erick Factor Chief Executive Officer

P ress Releases / JULY 11, 2022 Vancouver, BC – Cube Psytech Inc. (the “Company” or “ CUBE”), a biopharmaceutical and biotechnology company focused on the research and development of functional and psychedelic mushroom technologies for use in natural healthcare products, is pleased to announce the approval of the Company’s application to Health Canada to begin Phase 1 construction on its Ramara, Ontario property in conjunction with the issuance of a Health Canada Controlled Substance Dealers License. CUBE has begun the process of permitting and planning the Phase 1 buildout of its facility in accordance with the guidance of Health Canada. Health Canada has approved Cube Psytech’s plan, pending final inspection, to install new a Security Level 6 vault and grow rooms based on the Health Canada Directive on Physical Security Requirements for Controlled Substances and Drugs. Phase 1 construction is a retrofit of an existing 4000 sqft warehouse facility on the Ramara property. The facility will serve primarily as an R&D lab, with a secure vault and grow rooms. Further Phases (2-3) are planned once the Health Canada inspections of Phase 1 are complete. Phase 2 will add a large growing facility of 15,000 sqft and Phase 3 will add an additional 27,000 sqft of EU GMP certified lab, manufacturing and warehousing space. CUBE Co-Founder and CEO, Erick Factor had the following to say about the license approval: “I’m proud of our team. This is our second positive outcome with Health Canada and it comes ahead of schedule. We are on track with our business plan, building a strong foundation and creating a company that will be leaders in the space.” On Behalf of The Board of Directors Erick Factor Chief Executive Officer Contact: Erick Factor Investor Relations: investors@cubepsytech.com Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future of the Company's business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release Source: Cube Psytech Corporation

Press Releases / April 14th, 2022 Vancouver, BC – Cube Psytech Inc. (the “Company” or “ CUBE”), a biopharmaceutical and biotechnology company focused on the research and development of functional and psychedelic mushroom technologies for use in natural healthcare products, is pleased to announce the approval of the company’s application to Health Canada to use restricted drugs for scientific purposes, the following authorization is being granted to pursuant to section J.01.059 of Part J of the Food and Drug Regulations (FDR). CUBE has been authorised to carry out laboratory research with the restricted drugs, and to possess the restricted drugs for the purposes of such research. Specifically, Cube is authorized to conduct said research in the: “Optimization of psilocybin and its L-Tryptophan derivatives stabilities using different genetic strains of Psilocybe mushrooms”. The substances will be supplied in by Numinus Biosciences, a trusted leader in the production of the above controlled substances in a partnership previously outline in a company release. CUBE Co-Founder and Chief Science Officer, Srinivasa Reddy had the following to say about the license approval: “This a major step in the development of our company, the approval of this application allows us to proceed with the development of our protocols, advance the science in the field of psychedelic medicine and continue with our mission to create revolutionary patented properties for the treatment of PTSD, depression, anxiety, cancer and countless other mental and biological health concerns.” On Behalf of The Board of Directors Erick Factor Chief Executive Officer Contact: Erick Factor Investor Relations: investors@cubepsytech.com Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future of the Company's business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release Source: Cube Psytech Corporation

Could Washington be the next state to ease regulations on psychedelic use? It is what state Sen. Jesse Salomon hopes to do this session with his newly proposed bill. SB 5660 would legalise the use of psilocybin, a compound found in magic mushrooms, for therapeutic purposes, potentially providing a valuable mental health resource, according to Salomon. “It has shown a lot of promise through FDA-approved John Hopkins University studies and many other studies in terms of addiction recovery, and healing depression and anxiety,” - Sen. Jesse Salomon. “The first study was people with terminal illness who couldn’t get over the fact that they were going to die, and had tried all other mental health avenues to deal with that anxiety and depression,” he continued. “They were able to ease their symptoms through this process.” Other research on addiction treatment have showed consistent beneficial results. In 2016, ten patients suffering from alcoholism were given psilocybin and saw a 50% drop in their alcohol use after ten weeks. In a separate 2014 study from Johns Hopkins University, 15 smokers were given psilocybin treatments, and after six months, 12 of the 15 had quit smoking completely. Sen. Salomon also sees potential benefits for those who have suffered from mental illness as a result of the pandemic. “This is the mental health fix that we’ve been looking for,” he posited. “It is something that works for a lot of people who have not been successful in all other medical and mental health treatments, and with COVID driving up mental health problems, this is actually exactly what we need to give people an additional avenue to heal.” He further adds that "this is not the same as marijuana legalisation," explaining that in order to obtain psilocybin treatments, patients would still need to consult with service centres to discuss their medical concerns and mental health background.  “I have no intention in this bill to just have people go and buy it from a store,” he clarified. “This is integrated with mental health or self development.”

In the pharmaceutical industry, Canada has made significant announcements. Both psilocybin and MDMA are approved for medical usage. Patients with life-threatening mental diseases will be able to be treated as a result of this. Mushrooms contains the hallucinogenic chemical psilocybin. MDMA is the psychoactive substance commonly known as Ecstasy or Molly. Psilocybin has been touted as a breakthrough therapy for depression in recent years. Mike Tyson even stated that the mystical medicine saved his life. After being pushed down for decades, MDMA has gotten increasing favourable backing in recent years. It's been linked to helping those with PTSD and depression. Patients with mental diseases in Canada will be able to obtain both medications under the Special Access Program. When conventional therapy treatments fail, this initiative was created to provide patients with access to non-marketable medications. Right now, Canada is in the lead. If additional favourable results are achieved, other countries may consider following in their footsteps. Oregon was the first state in the United States to legalise magic mushrooms. In 2023, service centres are expected to open there.

Vancouver, BC – Cube Psytech Inc. (the “Company” or “ CUBE”), a biopharmaceutical and biotechnology company focused on the research and development of functional and psychedelic mushroom technologies for use in natural healthcare products, is announcing a new supply agreement. CUBE has agreed to terms with Psygen Labs Inc. (“Psygen”), a Canadian manufacturer of active pharmaceutical ingredients (APIs), and research chemicals produced to good manufacturing practices (GMP) standards. Psygen has applied for a Health Canada Dealer’s Licence which, if issued, will allow production of restricted drugs. The agreement secures supply, contingent on issue of a Dealer’s Licence to Psygen, of synthetic psilocybin for CUBE’s research and development, and serves to complement previous agreements to secure high quality extracts of naturally produced psilocybin. With the agreement, Psygen continues to add to their portfolio of research and development customers. “We are proud to add an excellent supplier to our vendors list.” Says Cube Psytech CEO / Co-Founder Erick Factor’. “Our continued mission to develop innovative high quality products depends on securing the best materials and Psygen is a leader in the field.” “Psygen understands the challenges obtaining a safe and reliable supply of psychedelic material for clinical research. We intend to be the solution as the leading supplier of psychedelic API’s on the global market.” says Nadia Van der Heyden, Psygen’s Director of Sales and Marketing. “We are happy to have Cube Psytech as a customer and look forward to their research developments in the future”. The agreement and supply of psilocybin to Cube Psytech will be in compliance with Health Canada guidelines. On Behalf of The Board of Directors Erick Factor Chief Executive Officer Contact: Erick Factor Investor Relations: investors@cubepsytech.com Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future of the Company's business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release Source: Cube Psytech Corporation

Cube Psytech Holdings is pleased to announce an approved site plan application from Ramara Township to build a 45,000 square foot faculty for psychedelic mushrooms. The facility operations will include research, cultivation, processing manufacturing and distribution of psylocibin as governed by Health Canada. This is a first of its kind psylocibin production facility in Ontario. Once the project is completed and licensed, it would be of the largest grow operations in the world with the potential to produce 34,000 Kgs of fresh psilocybin and 5,100 kg of dry weight. Cube Psytech made a land investment in at the beginning of 2021 purchasing 3.5 acres of land in the industrial zone of Ramara, Township. The municipality of Ramara, which is approximately one hour away from Toronto has been actively involved in the process. Cube Psytech anticipates that the project will advance quickly. Ramara’s planning department has already approved the preliminary construction design for the initial portion of the facility. Detailed plans for the first 5,000 sq-ft R&D facility have been submitted and approved by Ramara’s building department. Cube has assembled an in-house team of compliance experts that have successfully obtained multiple licences with Health Canada. Cube has submitted complete license application for research and development of psylocibin with Health Canada. “This is an important and significant milestone for Cube Psytech and the ongoing progression of psychedelic research in the medical space.” said Erick Factor, Cube’s Founder and CEO. “We have all of the architects, engineers and consultants in place, and with the full support of the municipality of Ramara, we are moving full steam ahead.” Once licensing is approved, Cube Psytech intends to use the licensed facility to expand research and development into: Psilocybin and psilocin production Psilocybin containing mushroom strain development Extraction and isolation of psilocybin and psilocin method development Formulation of investigational products for future clinical trials Supply of investigational products for clinical trials Once fully complete and licenced, the facility will employee over 100 people. The total investment of the project will be close to $10,000,000.00. “We wanted to make a land acquisition in Ontario where we felt there was promising upside in value over the next decade. Ramara Township is a great place to do business. It’s an excellent community with tremendous potential. We are very excited about our future here.” On Behalf of The Board of Directors Erick Factor Founder and Chief Executive Officer Contact: Erick Factor Investor Relations: investors@cubepsytech.com Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future of the Company's business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release Source: Cube Psytech Corporation